DAV (Disabled American Veterans) has launched an online resource to educate veterans, care providers and the public about psychedelic-assisted therapies for service-related mental health conditions.
A growing number of veterans are seeking alternative treatments after exhausting traditional options. Meanwhile, clinical researchers are advancing studies of MDMA, and plant medicines like psilocybin and ibogaine—at a time when legal access in the United States remains limited. As a result, many veterans travel abroad—often at significant personal risk and cost—to pursue these treatments.
DAV champions continued rigorous research into psychedelic-assisted therapies while stressing the importance of safety, oversight and evidence-based care. This new resource provides balanced information on this emerging issue.
“Psychedelics may be able to dramatically improve and even transform the lives of veterans suffering from invisible wounds,” said DAV CEO Barry Jesinoski. “Our goal is to provide clear, credible information so everyone involved can understand the science, the risks and what it means for their care.”
Read Also: Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
